** Brokerage Morningstar believes shares of infection
prevention co Nanosonics NAN.AX are over-valued, says EBIT
margins of co are set to fall due to lower-margin capital
revenue, among others
** Morningstar maintains A$4.00 fair value estimate for
"narrow-moat" Nanosonics
** Brokerage's fiscal 2024 EBIT forecast of A$14 million
($9.46 million), a 21% decrease on fiscal 2023, remains broadly
unchanged
** "Conditions are challenging given hospital budget
pressures" - brokerage
** Three of 11 analysts rate the stock "buy" or higher, six
"hold" and two "sell" or lower; their median PT is A$4.93 – LSEG
** Stock up 6.1% YTD, as of last close
($1 = 1.4795 Australian dollars)
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com;))